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Background: During percutaneous coronary intervention (PCI) in the emergency setting of ST-segment elevation myocardial infarction (STEMI), 
whether patients can comply with 12 months dual anti-platelet therapy after drug-eluting stenting (DES), is often uncertain. Thus if bare-metal stent 
(BMS) deployment could achieve low target vessel revascularization (TVR) rates in STEMI patients with ≥3.5mm culprit arteries, such a strategy 
could be beneficial.
Methods: We examined clinical outcomes of our institutional selective criteria for DES use, which recommends BMS in most patients with coronary 
arteries ≥3mm diameter.
Results: Among 1282 STEMI patients who underwent PCI during their initial hospitalization between October 2003-March 2010, 1059 patients 
received BMS (n=214, <3mm; n=333, 3-3.49mm; and n=512, ≥3.5mm) and 178 patients received DES (n=70, <3mm; n=66, 3-3.49mm; and 
n=42, ≥3.5mm). Among 554 patients (45%) who received stents ≥3.5mm, the mean age was 58±12 years, 85% male, and 5.6% presented with 
cardiogenic shock; the median culprit lesion length was 20mm (IQR: 15-25), and 72.5% had lesion classes B2/C. As patients who received BMS, 
compared with DES, were less likely to be diabetic (13% vs. 28.6%, p<0.001), have a culprit LAD artery (28.3% vs. 69%, p<0.001) and bifurcation 
lesions (11% vs. 31%, p<0.001), propensity scoring adjusted for these confounders. At 12 months, patients with BMS ≥3.5mm (n=512) had TVR 
rate of 2.2% and BMS 3-<3.5mm (n=333) TVR of 9.2% (p<0.001); nonfatal MI rates were 2.2% vs. 4.6%, p=0.082; rates of definite ST were 0.2% 
vs. 1.8%, p=0.062 and mortality was 4.4% vs. 8.0%, p=0.073 respectively. Respective TVR rates among patients with DES ≥3.5mm and BMS <3mm 
were 2.4% and 9%. On multivariable analysis, small vessels (<3mm) (OR:2.21[95%CI: 1.11-4.41], p=0.025); proximal LAD lesions (OR:2.53[1.18-
5.42], p=0.017); ostial lesions (OR: 3.71 [1.08-12.73], p=0.037) were predictors of TVR in the model accounting for DES and propensity scores.
Conclusions: In our study BMS deployment in STEMI patients with arteries ≥3.5mm was associated with low rates of TVR. Their use in this setting 
warrants comparison with DES deployment in future randomised clinical trials.
